* Eiger completes enrollment in phase 2 multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
No comments:
Post a Comment